Royalty Pharma: 2025 Financial Performance And Strategic Outlook [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerged as a major growth engine, surpassing traditional royalties in announced transaction value and offering structural advantages for biopharma funding. RPRX trades at a 50% discount to the sector median on forward earnings, despite strong recurring cash flows and a robust pipeline of clinical and regulatory catalysts. MarioGuti/iStock via Getty Images Thesis Royalty Pharma plc ( RPRX ) delivered decent financials in 2025. We saw double-digit growth in both Royalty Receipts and Portfolio Receipts. This led to very good returns on invested capital for the company. Elsewhere capital deployment remained This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View [Seeking Alpha]Seeking Alpha
- Royalty Pharma (NASDAQ:RPRX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
RPRX
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/13/26 - Form 4
- 2/13/26 - Form 4
- RPRX's page on the SEC website